Literature DB >> 2488207

Comparative pharmacokinetics of recombinant erythropoietin administered by the intravenous, subcutaneous, and intraperitoneal routes in continuous ambulatory peritoneal dialysis (CAPD) patients.

J R Boelaert1, M L Schurgers, E G Matthys, F M Belpaire, R F Daneels, M J De Cre, M G Bogaert.   

Abstract

The single dose pharmacokinetics of recombinant human erythropoietin (r-HuEPO) were compared in six continuous ambulatory peritoneal dialysis (CAPD) patients after intravenous (i.v.), subcutaneous (s.c.), and intraperitoneal (i.p.) administration of 300 U/kg. Intravenous administration gave results close to those obtained in hemodialysis patients, with a half-life of 11.2 h and a volume of distribution of 5.0% of body weight. After subcutaneous administration, the serum concentration rose slowly to plateau between 24 and 36 h, the area under the serum concentration vs. time curve from 6 to 72 h being 18.2% of that after intravenous administration. After intraperitoneal administration, the serum concentration was even lower, the area under the curve from 0 to 24 h was between 2.5 and 3.6% of that after intravenous administration, and 80% of the administered dose was recovered in the first peritoneal effluent after a 4-h dwell time.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2488207

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  14 in total

Review 1.  Pharmacokinetics of newer drugs in patients with renal impairment (Part I).

Authors:  J P Fillastre; E Singlas
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

2.  Treating renal anaemia with recombinant human erythropoietin: practical guidelines and a clinical algorithm.

Authors:  I C Macdougall; R D Hutton; I Cavill; G A Coles; J D Williams
Journal:  BMJ       Date:  1990-03-10

3.  An extended terminal half-life for darbepoetin alfa: results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis.

Authors:  Desmond Padhi; Liyun Ni; Blaire Cooke; Rafael Marino; Graham Jang
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 4.  The use of erythropoietin in renal failure.

Authors:  I C Macdougall; R D Hutton; G A Coles; J D Williams
Journal:  Postgrad Med J       Date:  1991-01       Impact factor: 2.401

Review 5.  Clinical pharmacokinetics during continuous ambulatory peritoneal dialysis.

Authors:  C A Taylor; E Abdel-Rahman; S W Zimmerman; C A Johnson
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

6.  The pharmacokinetics of recombinant human erythropoietin after subcutaneous injection at different sites.

Authors:  J D Jensen; L W Jensen; J K Madsen
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

7.  Pharmacokinetics of recombinant human erythropoietin applied subcutaneously to children with chronic renal failure.

Authors:  A Braun; R Ding; C Seidel; T Fies; A Kurtz; K Schärer
Journal:  Pediatr Nephrol       Date:  1993-02       Impact factor: 3.714

8.  Effects of azathioprine on response of renal anaemia to subcutaneous recombinant human erythropoietin.

Authors:  J E Howarth; H M Waters; D Shanks; K Hyde; J A Yin; C G Geary; E Anastassiades; D Howarth; R Gokal
Journal:  J Clin Pathol       Date:  1993-01       Impact factor: 3.411

9.  Intraperitoneal administration of recombinant human erythropoietin in children on continuous ambulatory peritoneal dialysis.

Authors:  R E Reddingius; C H Schröder; L A Monnens
Journal:  Eur J Pediatr       Date:  1992-07       Impact factor: 3.183

10.  Pharmacokinetics of recombinant human erythropoietin in children treated with continuous ambulatory peritoneal dialysis.

Authors:  R E Reddingius; C H Schröder; A M Koster; L A Monnens
Journal:  Eur J Pediatr       Date:  1994-11       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.